Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTAFR | P25105 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190195 | 0.88 | CNR1 (0.50) | RAB9APTAFRKMT2AMEN1TDP1 | |
| Hydrochloric Acid SCHEMBL3194128 | 0.87 | CNR1 (0.49) | RAB9APTAFRKMT2AMEN1TDP1 | |
| SCHEMBL3193046 | 0.81 | EGFR (0.40) | EGFRPPIDROCK2ROCK1 | |
| SCHEMBL3193038 | 0.81 | EGFR (0.40) | EGFRPPIDROCK2ROCK1 | |
| SCHEMBL3189069 | 0.79 | RAB9A (0.53) | RAB9AKMT2AMEN1TDP1MAPK1 | |
| SCHEMBL3187319 | 0.78 | CNR1 (0.41) | PPIDROCK2ROCK1ALDH1A1 | |
| SCHEMBL13454080 | 0.74 | PTAFR (0.45) | RAB9APTAFRKMT2AMEN1TDP1 | |
| SCHEMBL3189086 | 0.72 | CNR1 (0.45) | PPID | |
| SCHEMBL3194373 | 0.71 | CNR1 (0.46) | EGFRPPID | |
| SCHEMBL13454414 | 0.71 | EGFR (0.52) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | ADOLOR CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671052-B2 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-20060074086-A1 | Phenyl derivatives and methods of use | ADOLOR CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074086-A1 | Phenyl derivatives and methods of use | CNR2, CNR1, GPR119 | EGFR 2460/4885RAB9A 2079/4885PTAFR 225/4885 |
| US-20100168108-A1 | PHENYL DERIVATIVES AND METHODS OF USE | CNR2, CNR1, GPR119 | EGFR 2460/4885RAB9A 2079/4885PTAFR 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.